NNC 0772 | CAS# 141696-67-5 | dopamine D-1 receptor antagonist

MedKoo Cat#: 414441 | Name: NNC 0772

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NNC 0772 is a dopamine D-1 receptor antagonist

Chemical Structure

NNC 0772

CAS#141696-67-5

Theoretical Analysis

MedKoo Cat#: 414441

Name: NNC 0772

CAS#: 141696-67-5

Chemical Formula: C19H21Cl2NO2

Exact Mass: 365.0949

Molecular Weight: 366.28

Elemental Analysis: C, 62.30; H, 5.78; Cl, 19.36; N, 3.82; O, 8.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

NNC-0772; NNC0772; NNC 0772

IUPAC/Chemical Name

1H-3-Benzazepin-7-ol, 8-chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-, hydrochloride, (5R)-

InChi Key

JDWPTZHFKLBAPI-NTISSMGPSA-N

InChi Code

InChI=1S/C19H20ClNO2.ClH/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14;/h2-4,9-10,16,22H,5-8,11H2,1H3;1H/t16-;/m0./s1

SMILES Code

OC1=C(Cl)C=C2CCN(C)C[C@@H](C3=C(OCC4)C4=CC=C3)C2=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 366.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hansen KT, Thomsen KF, Bundgaard H. Glucuronidation of the dopamine D-1 receptor antagonists NNC 0756 and NNC 0772 in liver microsomes. Drug Metab Dispos. 1992 Mar-Apr;20(2):172-8. PMID: 1352206. 2: Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. doi: 10.1016/0014-2999(92)90578-r. PMID: 1397049. 3: Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Grønvald F, Swahn CG, Hall H, Sedvall G. [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol. 1993 Nov;20(8):945-53. doi: 10.1016/0969-8051(93)90095-c. PMID: 8298574. 4: Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl). 1993;113(2):149-56. doi: 10.1007/BF02245691. PMID: 7855175. 5: Laihinen AO, Rinne JO, Ruottinen HM, Någren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med. 1994 Dec;35(12):1916-20. PMID: 7989969. 6: Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea- Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109. doi: 10.1002/(SICI)1098-2396(199905)32:2<93::AID-SYN3>3.0.CO;2-C. PMID: 10231129. 7: Karlsson P, Farde L, Halldin C, Sedvall G, Ynddal L, Sloth-Nielsen M. Oral administration of NNC 756--a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology (Berl). 1995 May;119(1):1-8. doi: 10.1007/BF02246046. PMID: 7675940. 8: Lublin H, Gerlach J, Mørkeberg F. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Psychopharmacology (Berl). 1994 Apr;114(3):495-504. doi: 10.1007/BF02249341. PMID: 7855208. 9: Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinin H, Taiminen T, Någren K, Eskola O, Jääskeläinen SK. Altered dopamine D2 receptor binding in atypical facial pain. Pain. 2003 Nov;106(1-2):43-8. doi: 10.1016/s0304-3959(03)00275-6. PMID: 14581109. 10: Pascoe PJ, Taylor PM. Effects of dopamine antagonists on alfentanil-induced locomotor activity in horses. Vet Anaesth Analg. 2003 Jul;30(3):165-71. doi: 10.1046/j.1467-2995.2003.00134.x. PMID: 14498848.